These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17317170)

  • 1. Optimization of halopemide for phospholipase D2 inhibition.
    Monovich L; Mugrage B; Quadros E; Toscano K; Tommasi R; LaVoie S; Liu E; Du Z; LaSala D; Boyar W; Steed P
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2310-1. PubMed ID: 17317170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.
    Lewis JA; Scott SA; Lavieri R; Buck JR; Selvy PE; Stoops SL; Armstrong MD; Brown HA; Lindsley CW
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1916-20. PubMed ID: 19268584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
    Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists.
    Bonnefous C; Vernier JM; Hutchinson JH; Chung J; Reyes-Manalo G; Kamenecka T
    Bioorg Med Chem Lett; 2005 Feb; 15(4):1197-200. PubMed ID: 15686941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors.
    Shen HC; Ding FX; Deng Q; Xu S; Tong X; Zhang X; Chen Y; Zhou G; Pai LY; Alonso-Galicia M; Roy S; Zhang B; Tata JR; Berger JP; Colletti SL
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5716-21. PubMed ID: 19700315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depolarization-induced differentiation of PC12 cells is mediated by phospholipase D2 through the transcription factor CREB pathway.
    Banno Y; Nemoto S; Murakami M; Kimura M; Ueno Y; Ohguchi K; Hara A; Okano Y; Kitade Y; Onozuka M; Murate T; Nozawa Y
    J Neurochem; 2008 Mar; 104(5):1372-86. PubMed ID: 18004999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2alpha: optimization of in vitro potency and rat pharmacokinetics for oral efficacy.
    Lee KL; Behnke ML; Foley MA; Chen L; Wang W; Vargas R; Nunez J; Tam S; Mollova N; Xu X; Shen MW; Ramarao MK; Goodwin DG; Nickerson-Nutter CL; Abraham WM; Williams C; Clark JD; McKew JC
    Bioorg Med Chem; 2008 Feb; 16(3):1345-58. PubMed ID: 17998165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based optimization of a potent class of arylamide FMS inhibitors.
    Meegalla SK; Wall MJ; Chen J; Wilson KJ; Ballentine SK; Desjarlais RL; Schubert C; Crysler CS; Chen Y; Molloy CJ; Chaikin MA; Manthey CL; Player MR; Tomczuk BE; Illig CR
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3632-7. PubMed ID: 18495479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The identification of pyrazolo[1,5-a]pyridines as potent p38 kinase inhibitors.
    Cheung M; Harris PA; Badiang JG; Peckham GE; Chamberlain SD; Alberti MJ; Jung DK; Harris SS; Bramson NH; Epperly AH; Stimpson SA; Peel MR
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5428-30. PubMed ID: 18818075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1,3-disubstituted-4-aminopyrazolo [3, 4-d] pyrimidines, a new class of potent inhibitors for phospholipase D.
    Kulkarni A; Quang P; Curry V; Keyes R; Zhou W; Cho H; Baffoe J; Török B; Stieglitz K
    Chem Biol Drug Des; 2014 Sep; 84(3):270-81. PubMed ID: 24641677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2.
    Koch T; Seifert A; Wu DF; Rankovic M; Kraus J; Börner C; Brandenburg LO; Schröder H; Höllt V
    J Neurochem; 2009 Aug; 110(4):1288-96. PubMed ID: 19519662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privileged structure that engenders PLD2 selectivity.
    Lavieri R; Scott SA; Lewis JA; Selvy PE; Armstrong MD; Alex Brown H; Lindsley CW
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2240-3. PubMed ID: 19299128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors.
    Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5456-9. PubMed ID: 18835164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and pharmacological evaluation of N-bicyclo-5-chloro-1H-indole-2-carboxamide derivatives as potent glycogen phosphorylase inhibitors.
    Onda K; Shiraki R; Ogiyama T; Yokoyama K; Momose K; Katayama N; Orita M; Yamaguchi T; Furutani M; Hamada N; Takeuchi M; Okada M; Ohta M; Tsukamoto S
    Bioorg Med Chem; 2008 Dec; 16(23):10001-12. PubMed ID: 18952447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further evaluation of novel structural modifications to scaffolds that engender PLD isoform selective inhibition.
    O'Reilly MC; Scott SA; Brown HA; Lindsley CW
    Bioorg Med Chem Lett; 2014 Dec; 24(24):5553-5557. PubMed ID: 25466173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of a novel indoledione class of long chain fatty acid elongase 6 (ELOVL6) inhibitors.
    Takahashi T; Nagase T; Sasaki T; Nagumo A; Shimamura K; Miyamoto Y; Kitazawa H; Kanesaka M; Yoshimoto R; Aragane K; Tokita S; Sato N
    J Med Chem; 2009 May; 52(10):3142-5. PubMed ID: 19388647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of N-alkyl glycine amides as potent inhibitors of leukotriene A4 hydrolase.
    Ye B; Bauman J; Chen M; Davey D; Khim SK; King B; Kirkland T; Kochanny M; Liang A; Lentz D; May K; Mendoza L; Phillips G; Selchau V; Schlyer S; Tseng JL; Wei RG; Ye H; Parkinson J; Guilford WJ
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3891-4. PubMed ID: 18586492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-(2-Carboxyindol-5-yloxy)propan-2-ones as inhibitors of human cytosolic phospholipase A2alpha: synthesis, biological activity, metabolic stability, and solubility.
    Fritsche A; Elfringhoff AS; Fabian J; Lehr M
    Bioorg Med Chem; 2008 Apr; 16(7):3489-500. PubMed ID: 18321717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent and specific fructose-1,6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes.
    Dang Q; Kasibhatla SR; Reddy KR; Jiang T; Reddy MR; Potter SC; Fujitaki JM; van Poelje PD; Huang J; Lipscomb WN; Erion MD
    J Am Chem Soc; 2007 Dec; 129(50):15491-502. PubMed ID: 18041834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.